Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ruxolitinib in proliferative chronic myelomonocytic leukemia (CMML)
2013-004370-10Phase 2Terminated
- Sponsor
- Grupo Español de Síndromes Mielodisplásicos
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in chronic myelomonocytic leukemia (CMML), sponsored by Grupo Español de Síndromes Mielodisplásicos. Primary endpoint: Primary: spleen size reduction at week 48. Started Feb 2014; status: terminated.
02
Drugs
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2013-004370-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004370-10.